1. bookVolume 35 (2022): Issue 2 (August 2022)
Journal Details
License
Format
Journal
eISSN
2300-6676
First Published
30 May 2014
Publication timeframe
4 times per year
Languages
English
access type Open Access

Coumarin derivatives against amyloid-beta 40 – 42 peptide and tau protein

Published Online: 02 Sep 2022
Volume & Issue: Volume 35 (2022) - Issue 2 (August 2022)
Page range: 67 - 74
Received: 13 Mar 2022
Accepted: 17 Jun 2022
Journal Details
License
Format
Journal
eISSN
2300-6676
First Published
30 May 2014
Publication timeframe
4 times per year
Languages
English
Abstract

In preclinical studies, simple coumarins (scoparone, limettin) and furanocoumarins (imperatorin, xanthotoxin, bergapten) have already found to demonstrate procognitive abilities. This suggests that they hold antioxidative, anti-inflammatory and inhibitory action towards acetylcholinesterase activities. However, little is known about their influence on the amyloidal structure formation, the leading cause of Alzheimer’s disease (AD). In vitro and in cellulo assays were applied to evaluate the effect of selected coumarins on the different stages of Aβ40/42 and tau protein aggregation. Kinetic analyses were performed to evaluate their inhibiting abilities in time. Limettin revealed the most potent inhibiting profile towards Aβ40 aggregation, however, all tested compounds presented low influence on Aβ42 and tau protein aggregation inhibition. Despite the preliminary stage of the project, the promising effects of coumarins on Aβ40 aggregation were shown. This suggests the coumarin scaffold can serve as a potential multitarget agent in AD treatment, but further studies are required to confirm this.

Keywords

1. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches. Lancet Nerol. 2021;20(1):68-80.10.1016/S1474-4422(20)30412-9 Search in Google Scholar

2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002; 297:353-6.10.1126/science.107299412130773 Search in Google Scholar

3. Dasari M, Espargaro A, Sabate R, Lopez Del Amo JM, Fink U, Grelle G, et al. Bacterial inclusion bodies of Alzheimer’s disease β-amyloid peptides can be employed to study native-like aggregation intermediate states. Chembiochem. 2011;12:407-23.10.1002/cbic.20100060221290543 Search in Google Scholar

4. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: implications for early intervention and therapeutics. Biochim Biophys Acta. 2011;1812:1359-70.10.1016/j.bbadis.2011.08.005318517221871956 Search in Google Scholar

5. Govoni S, Mura E, Preda S, Racchi M, Lanni C, Grilli M, et al. Dangerous liaisons between beta-amyloid and cholinergic neurotransmission. Curr Pharm Des. 2014;20:2525-38.10.2174/1381612811319999050323859550 Search in Google Scholar

6. Tang BL. Amyloid Precursor Protein (APP) and GABAergic neurotransmission. Cells. 2019;8:550.10.3390/cells8060550662794131174368 Search in Google Scholar

7. Girek M, Szymański P. Tacrine hybrids as multi-target-directed ligands in Alzheimer’s disease: influence of chemical structures on biological activities. Chem Papers. 2018;73:269-89.10.1007/s11696-018-0590-8 Search in Google Scholar

8. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48:6523-43.10.1021/jm058225d16220969 Search in Google Scholar

9. Skalicka-Woźniak K, Orhan IE, Cordell GA, Nabavi SM, Budzyńska B. Implication of coumarins towards central nervous system disorders. Pharmacol Res. 2016;103:188-203.10.1016/j.phrs.2015.11.02326657416 Search in Google Scholar

10. Rao VR. Antioxidant Agents. Advances in structure and activity relationship of coumarin derivatives. London; 2016:137-50.10.1016/B978-0-12-803797-3.00007-2 Search in Google Scholar

11. Wang L, Yin YL, Liu XZ, Shen P, Zheng YG, Lan XR, et al. Current understanding of metal ions in the pathogenesis of Alzheimer’s disease. Transl Neurodegener. 2020;9 :10.10.1186/s40035-020-00189-z Search in Google Scholar

12. Budzynska B, Boguszewska-Czubara A, Kruk-Slomka M, Skalicka-Wozniak K, Michalak A, Musik I, et al. Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice. Psychopharmacology (Berl). 2015;232:931-42.10.1007/s00213-014-3728-6 Search in Google Scholar

13. Espargaró A, Medina A, di Pietro O, Muñoz-Torrero D, Sabate R. Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs. Scientific Reports. 2016;6:1-8.10.1038/srep23349 Search in Google Scholar

14. Kowalczyk J, Budzyńska B, Kurach Ł, Pellegata D, Sayed NS, Gertsch J, et al. Neuropsychopharmacological profiling of scoparone in mice. Sci Rep. 2022;12:822.10.1038/s41598-021-04741-3 Search in Google Scholar

15. Kozioł E, Skalicka-Woźniak K. Imperatorin–pharmacological meaning and analytical clues: profound investigation. Phytochem Rev. 2016;15:627-49.10.1007/s11101-016-9456-2 Search in Google Scholar

16. Espargaró A, Sabaté R, Ventura S. Kinetic and thermodynamic stability of bacterial intracellular aggregates. FEBS Letters. 2008;582: 3669-73.10.1016/j.febslet.2008.09.049 Search in Google Scholar

17. Espargaró A, Pont C, Gamez P, Muñoz-Torrero D, Sabate R. Amyloid pan-inhibitors: One family of compounds to cope with all conformational diseases. ACS Chem Neurosci. 2019;10:1311-7.10.1021/acschemneuro.8b00398 Search in Google Scholar

18. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol. 1999;155:853-62.10.1016/S0002-9440(10)65184-X Search in Google Scholar

19. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535-9.10.1038/416535a11932745 Search in Google Scholar

20. Li JJ, Dolios G, Wang R, Liao FF. Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression. PLoS One. 2014;9(3):e90770.10.1371/journal.pone.0090770394247824595404 Search in Google Scholar

21. Yang J, Zhu B, Yin W, Han Z, Zheng C, Wang P, et al. Differentiating Aβ40 and Aβ42 in amyloid plaques with a small molecule fluorescence probe. Chem Sci. 2020;11:5238-45.10.1039/D0SC02060E Search in Google Scholar

22. Gu L, Guo Z. Alzheimer’s Aβ42 and Aβ40 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126:305.10.1111/jnc.12202371683223406382 Search in Google Scholar

23. Takomthong P, Waiwut P, Yenjai C, Sripanidkulchai B, Reubroycharoen P, Lai R, et al. Structure-activity analysis and molecular docking studies of coumarins from Toddalia asiatica as multifunctional agents for Alzheimer’s disease. Biomedicines. 2020;8(5):107.10.3390/biomedicines8050107727774832370238 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo